Administrative Core
行政核心
基本信息
- 批准号:10204118
- 负责人:
- 金额:$ 27.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdvanced DevelopmentAdvisory CommitteesAnticonvulsantsCalendarChemicalsCholinesterase InhibitorsCollaborationsCommittee MembersCommunicationCommunitiesDataDatabase Management SystemsDevelopmentEducational workshopEnsureEnvironmental HealthEquipment and supply inventoriesEventFederal GovernmentFosteringFundingGeneral PopulationGoalsGovernment AgenciesGrantHuman ResourcesIACUCIntellectual PropertyIntoxicationInvestigational DrugsIsoflurophateLaboratoriesLeadLeadershipLegal patentLogisticsManuscriptsMedical ResearchMissionMonitorOnline SystemsOrganophosphatesParaoxonPicrotoxinPoliciesProceduresProtocols documentationPubMedReadinessReagentRegulationReportingResearchResearch ActivityResearch InstituteResearch PersonnelResearch Project GrantsResource SharingRoleSafetySecureSecuritySeizuresSeriesSomanStrategic PlanningSystemTechnology TransferTherapeuticTherapeutic AgentsTimeLineTrainingUnited States Food and Drug AdministrationUnited States National Institutes of HealthUniversitiesWorkauthoritycentral databasechemical threatdata exchangedata managementdata sharingeducation researchimprovedinterestmedical countermeasuremeetingsnoveloperationpreventprogramsreceptorresearch and developmentstatisticssuccesssynergismtetramethylenedisulfotetraminetherapeutic developmentweb site
项目摘要
Project Summary – Administrative Core
The overall goal of the UC Davis CounterACT Center of Excellence is to identify and advance improved medical
countermeasures for stopping seizures and preventing long-term consequences of acute intoxication with
chemical threat agents, specifically organophosphate cholinesterase inhibitors like diisopropylfluorophosphate
(DFP), paraoxon and soman, or GABAA receptor blockers like tetramethylenedisulfotetramine (TETS) and
picrotoxin. The UC Davis CounterACT Center comprises three projects, three scientific cores, a research
education core and multiple committees — all of which must work closely together to ensure success. The role
of the Administrative Core is to oversee and coordinate the scientific and administrative operations of the
Center's activities and to foster interactions and synergism among Center research projects and scientific cores,
ultimately ensuring the Center meets annual milestones established in collaboration with NIH CounterACT
program officer(s). Additionally, the Administrative Core will coordinate interactions with the UC Davis
administration and external entities, such as the NIH CounterACT administration, the Center's External Advisory
Committee, the larger CounterACT research community, the U.S. Food and Drug Administration (FDA), the
Biomedical Advanced Research and Development Authority (BARDA), and commercial partners. The Core's
objectives are: (1) Develop a strategic plan for achieving annual Center milestones and ensure its effective and
efficient implementation; (2) Provide scientific leadership and logistical support to coordinate and integrate
Center activities and promote interactions among Center investigators; (3) Facilitate data and resource sharing
among Center investigators and other CounterACT investigators; (4) Provide budgetary oversight and grant
management; (5) Ensure the safety and security of personnel, materials, data and facilities; (6) Coordinate the
development of intellectual property (IP) strategies and the transitioning of leads for advanced development; (7)
Coordinate with FDA, BARDA and other federal government agencies; and (8) Identify, engage and coordinate
communications with commercial partners.
项目摘要 – 行政核心
加州大学戴维斯分校 CounterACT 卓越中心的总体目标是确定并推进改进的医疗
停止癫痫发作和预防急性中毒长期后果的对策
化学威胁剂,特别是有机磷酸酯胆碱酯酶抑制剂,如二异丙基氟磷酸盐
(DFP)、对氧磷和梭曼,或 GABAA 受体阻滞剂,如四亚甲基二磺四胺 (TETS) 和
加州大学戴维斯分校 CounterACT 中心包括三个项目、三个科学核心、一项研究。
教育核心和多个委员会——所有这些都必须紧密合作以确保成功。
行政核心的职责是监督和协调科学和行政运作
中心的活动并促进中心研究项目和科学核心之间的相互作用和协同作用,
最终确保该中心达到与 NIH CounterACT 合作建立的年度里程碑
此外,行政核心将协调与加州大学戴维斯分校的互动。
行政部门和外部实体,例如 NIH CounterACT 行政部门、中心的外部咨询
委员会、更大的 CounterACT 研究团体、美国食品和药物管理局 (FDA)、
生物医学高级研究与开发局 (BARDA) 以及 The Core 的商业合作伙伴。
目标是: (1) 制定实现中心年度里程碑的战略计划,并确保其有效性和
(二)科学领导、统筹协调、后勤保障
(三)促进数据和资源共享
中心调查员和其他 CounterACT 调查员之间; (4) 提供预算监督和拨款
(五)确保人员、物资、数据和设施的安全;
(七)制定知识产权(IP)战略并转变先进发展的领先地位;
与 FDA、BARDA 和其他联邦政府机构协调;以及 (8) 确定、参与和协调
与商业伙伴的沟通。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pamela J Lein其他文献
Pamela J Lein的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pamela J Lein', 18)}}的其他基金
Project 1: Reduction of Pro-Inflammatory Signaling
项目 1:减少促炎症信号传导
- 批准号:
10684082 - 财政年份:2022
- 资助金额:
$ 27.48万 - 项目类别:
Ketogenic diet approaches to slow disease progression in a rat model of Alzheimer's disease
生酮饮食方法可减缓阿尔茨海默病大鼠模型的疾病进展
- 批准号:
9977496 - 财政年份:2020
- 资助金额:
$ 27.48万 - 项目类别:
Identifying Molecular Targets for the Proconvulsant Activity of TETS
确定 TETS 促惊厥活性的分子靶点
- 批准号:
9905564 - 财政年份:2019
- 资助金额:
$ 27.48万 - 项目类别:
Does air pollution increase risk of AD in a genetically susceptible animal model?
空气污染是否会增加遗传易感动物模型患 AD 的风险?
- 批准号:
9126737 - 财政年份:2016
- 资助金额:
$ 27.48万 - 项目类别:
Mitigation of Neurological Damage Following Seizures
减轻癫痫发作后的神经损伤
- 批准号:
10204125 - 财政年份:2012
- 资助金额:
$ 27.48万 - 项目类别:
Novel anticonvulsant and neuroprotective therapies for TETS and OP intoxication
针对 TETS 和 OP 中毒的新型抗惊厥药和神经保护疗法
- 批准号:
9142832 - 财政年份:2012
- 资助金额:
$ 27.48万 - 项目类别:
Novel Anticonvulsant and Neuroprotective Therapies for TETS and OP Intoxication
针对 TETS 和 OP 中毒的新型抗惊厥和神经保护疗法
- 批准号:
10204117 - 财政年份:2012
- 资助金额:
$ 27.48万 - 项目类别:
Novel anticonvulsant and neuroprotective therapies for TETS and OP intoxication
针对 TETS 和 OP 中毒的新型抗惊厥药和神经保护疗法
- 批准号:
8925299 - 财政年份:2012
- 资助金额:
$ 27.48万 - 项目类别:
相似国自然基金
减少编程错误:基于认证内核的全新的快捷依赖类型PiSigma高级编程语言开发
- 批准号:61070023
- 批准年份:2010
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Early life stress impacts molecular and network properties that bias the recruitment of pro-stress BLA circuits
早期生活压力会影响分子和网络特性,从而影响促压力 BLA 回路的募集
- 批准号:
10820820 - 财政年份:2023
- 资助金额:
$ 27.48万 - 项目类别:
Strategy for Improving Stroke Treatment Response (SISTER) Trial
改善中风治疗反应策略 (SISTER) 试验
- 批准号:
10595947 - 财政年份:2023
- 资助金额:
$ 27.48万 - 项目类别:
Achieving Maternal Equity and Transforming Health through Implementation Science and Training (AMETHIST@Penn)
通过实施科学和培训实现孕产妇公平并改变健康状况 (AMETHIST@Penn)
- 批准号:
10748593 - 财政年份:2023
- 资助金额:
$ 27.48万 - 项目类别:
Novel molecular mechanisms of vascular smooth muscle cell-mediated large and small artery calcification
血管平滑肌细胞介导大小动脉钙化的新分子机制
- 批准号:
10670415 - 财政年份:2022
- 资助金额:
$ 27.48万 - 项目类别: